A four year dose-response study of recombinant human growth hormone treatment of growth hormone deficient children: effects on growth, bone growth and bone mineralization

Radetti, Giorgio; Buzi, Fabio; Paganini, Chiara; Martelli, Catherine; Adami, Silvano

doi:10.1530/eje.0.1420042

Cited by 13 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, local overexpression of IGF-I has been shown to increase trabecular bone formation and osteoblastic cell proliferation in unloaded rats (21). At the higher doses employed in this study, however, GH seems to have mainly a permissive role in mineralization, since in a previous study we could not find any difference in the bone mineral density of the radius and of the metacarpal bone in two groups of GHD children similarly treated (22).…”

Section: Discussioncontrasting

confidence: 40%

Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children

Radetti¹,

D’Addato²,

Gatti³

et al. 2006

eur j endocrinol

View full text Add to dashboard Cite

Objective: The aim was to investigate the effects of two different GH dosage regimens on growth, bone geometry and bone strength. Subjects and methods: Final height; parentally adjusted final height; the metacarpal index (MI) SDS, the inner and outer diameters; and the total cross-sectional area (CSA), cortical CSA, medullary CSA and bone strength (Bending Breaking Resistance Index (BBRI)) were evaluated at the metacarpal site in two cohorts of GH-deficient children, treated with two different doses of GH. Group 1 (38 patients) was treated with 0.16 mg/kg body weight per week of GH and group 2 (37 patients) with 0.3 mg/kg per week. Results: At the end of treatment, with group 1 vs group 2, height SDS was 20.84^1.07 vs 2 0.46^0.76, and parentally adjusted height SDS was 0.14^1.08 vs 0.27^0.82. Parentally adjusted relative height gain was 1.14^0.89 vs 2.14^0.72 SDS (P , 0.0001). MI SDS was 0.58^1.31 vs 2 0.42^1.54 (P , 0.005). MI SDS gain was 0.07^1.41 vs 20.35^1.85. There was no difference between groups in the outer and inner diameter, in the total and cortical CSAs, whereas medullary CSA was higher in group 2 (P , 0.05). BBRI was 10.02^5.37 vs 11.52^5.49 cm 3 , and BBRI gain was 3.33^5.06 vs 6.88^6.65 (P ¼ 0.01). P values were assessed using student's t-test. Conclusion: Higher GH doses result in a greater height gain and improved bone strength.European Journal of Endocrinology 154 479-482

show abstract

Section: Discussioncontrasting

confidence: 40%

Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children

Radetti¹,

D’Addato²,

Gatti³

et al. 2006

eur j endocrinol

View full text Add to dashboard Cite

show abstract

“…European and Japanese investigators have also observed an increase in height gain in terms of HSDS or height velocity SDS in cohorts of prepubertal children with GHD treated with rhGH for up to 4 years at two different doses (47 and 71 μg/kg/day) [18,19]. A comparative analysis of two large observational registries tracking the efficacy and safety of long-term Norditropin® treatment showed that >75% of prepubertal children with GHD and other short stature indications reached a height within the normal range (i.e.…”

Section: Discussionmentioning

confidence: 99%

Prepubertal Children with Growth Hormone Deficiency Treated for Four Years with Growth Hormone Experience Dose-Dependent Increase in Height, but Not in the Rate of Puberty Initiation

et al. 2013

View full text Add to dashboard Cite

Background/Aims: Limited data exist on long-term dose response to recombinant human growth hormone (rhGH) in prepubertal GH-deficient (GHD) children. The effect of low, intermediate, and high-dose rhGH (25, 50, and 100 μg/kg/day, respectively) on growth and puberty in children with GHD was investigated for 48 months. Methods: A prospective, dose-response study in 111 patients (aged 3-16 years) evaluated growth velocity (cm/year), height standard deviation score (HSDS), corrected HSDS, bone age/chronologic age ratio, body mass index SDS, and the percentage starting puberty. Results: Dose-related increases were observed in growth velocity (p < 0.001), HSDS (p < 0.001), and corrected HSDS (p < 0.001) from baseline to 48 months. Increases in the bone age/chronologic age ratio (p = 0.043) and body mass index SDS (p = 0.018) occurred up to 36 months at intermediate and high doses versus low-dose rhGH; increases at 48 months were not significant. No significant differences in growth were found between intermediate and high doses of rhGH. Percentages of rhGH-treated patients starting puberty at each dose were equivalent (p = 0.607). Conclusions: rhGH, 50 and 100 μg/kg/day, induced greater growth than 25 μg/kg/day without altering the proportion of children starting puberty. The maximum approved dose for pubertal patients (100 μg/kg/day) is not required or recommended for prepubertal children with GHD.

show abstract

“…BA acceleration was also verified by the reduction in CA/BA ratio in all patient groups after the first and second years of treatment. Radetti et al (15) have reported that high dose GH treatment did not significantly advance BA. Frindik et al (16) have proposed that patients with mildly delayed BA before puberty showed faster BA acceleration during puberty with GH treatment compared to those with more severe BA delay.…”

Section: Discussionmentioning

confidence: 97%

Does Growth Hormone Treatment Advance Bone Age?

Salı¹,

Sağlam²,

Eren³

et al. 2017

jcp

View full text Add to dashboard Cite

Giriş ve Amaç: Büyüme hormonu (BH) tedavisi, erken epifiz kapanmasına neden olan kemik matürasyonundaki ilerleme konusunda artan endişelerle, kemik matürasyonuna uyarıcı etkide bulunabilir. Bu çalışmada, bu olasılığın araştırılması ve ilerlemiş kemik matürasyonunun tahmini veya son boya etkisinin olup olmadığının saptanmasını amaçladık. Yöntem ve Gereçler: 1995-2005 tarihleri arasında BH tedavisi alan toplam 230 hastanın verileri retrospektif olarak değerlendirildi. Hastalar; izole BH eksikliği (Grup 1), Turner sendromu (Grup 2) ve diğer (Grup 3) olarak ayrıldı. Önceki el bileği X-ray verileri tıbbi kayıtlardan çıkarıldı ve klinik vizitlerde el bilek X-ray istendi. Kemik yaşı (KY) değerlendirilmesi Greulich ve Pyle atlasına göre yapıldı. Tahmini yetişkin boyu, KY kullanılarak Bayley ve Pinneau metoduna göre yapıldı. Bazal tahmini boy ile tedavinin 1. ve 2. yılındaki tahmini boy, takvim yaş (TY)-KY ve TY/KY değişkenlikleri kullanılarak değerlendirildi.Bulgular: Her üç grupta boy SDS anlamlı olarak arttı (p<0,05). Grup 1 ve 2'deki TY-KY, tedavinin 1. ve 2. yılı süresince azaldı (p<0,05). KY'ndaki ilerleme, TY/KY oranındaki azalma ile teyit edildi.Bununla beraber, KY ilerlemesine karşın öngörülen boy olumsuz etkilenmedi.Tartişma ve Sonuç: TY-KY ve TY/KY oranındaki azalma kanıtı olarak BH, KY'nı artırdı. Bununla beraber, tahmini boy iki yıllık tedavi kohortumuzda ilerlemiş kemik matürasyonuna ters olarak etkilenmedi. Bu konu, kemik yaşının daha çok ilerlediği puberte prekoks gibi hasta gruplarında araştırılmalıdır.

show abstract

A four year dose-response study of recombinant human growth hormone treatment of growth hormone deficient children: effects on growth, bone growth and bone mineralization

Cited by 13 publications

References 23 publications

Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children

Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children

Prepubertal Children with Growth Hormone Deficiency Treated for Four Years with Growth Hormone Experience Dose-Dependent Increase in Height, but Not in the Rate of Puberty Initiation

Does Growth Hormone Treatment Advance Bone Age?

Contact Info

Product

Resources

About